thalidomide has been researched along with Myopathies, Nemaline in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Myopathies, Nemaline: A group of inherited congenital myopathic conditions characterized clinically by weakness, hypotonia, and prominent hypoplasia of proximal muscles including the face. Muscle biopsy reveals large numbers of rod-shaped structures beneath the muscle fiber plasma membrane. This disorder is genetically heterogeneous and may occasionally present in adults. (Adams et al., Principles of Neurology, 6th ed, p1453)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance is a rare subacute adult-onset myopathy." | 1.48 | Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen. ( Boonyapisit, K; Kumutpongpanich, T; Nishino, I; Owattanapanich, W; Tanboon, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumutpongpanich, T | 1 |
| Owattanapanich, W | 1 |
| Tanboon, J | 1 |
| Nishino, I | 1 |
| Boonyapisit, K | 1 |
| Naddaf, E | 1 |
| Milone, M | 1 |
| Kansagra, A | 1 |
| Buadi, F | 1 |
| Kourelis, T | 1 |
| Montagnese, F | 1 |
| Portaro, S | 1 |
| Musumeci, O | 1 |
| Migliorato, A | 1 |
| Moggio, M | 1 |
| Fagiolari, G | 1 |
| Rodolico, C | 1 |
3 other studies available for thalidomide and Myopathies, Nemaline
| Article | Year |
|---|---|
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen.
Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunosuppressive Agents; | 2018 |
Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosu | 2019 |
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Middle | 2015 |